Navigation Links
NeurogesX to Present at Two February Investor Conferences
Date:2/8/2011

any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements regarding the potential benefits of the new director appointee to the NeurogesX Board of Directors; and the potential submission to the U.S. Food and Drug Administration of a supplemental new drug application for label expansion of Qutenza.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to manufacture and supply of Qutenza; unexpected adverse side effects of Qutenza; physician or patient reluctance to use Qutenza, despite the Company's efforts and strategies to commercialize Qutenza; and difficulties or delays in the further development of Qutenza and efforts towards label expansion; and potential competitors and competitive products. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.Stephen Ghiglieri

Chief Financial Officer

(650) 358-3310The Ruth GroupSara Pellegrino (investors)

(646) 536-7002

spellegrino@theruthgroup.comJason Rando (media)

(646) 536-7025

jrando@theruthgroup.com
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
... with Fractionated Lasers Or in ... the Eyes, WALTHAM, Mass., Jan. 24 When it ... no longer the only option. According to the,American Academy of ... who is interested in non-surgical options to obtain the,best results. ...
Cached Medicine Technology:Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 2Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 3Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 4
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... she had an aneurysm, she figured an invasive brain surgery ... devastated," said Wakulich, who is 56 years old and lives ... diagnosis. Then I met Dr. Bernard Bendok who told me ... It was something I didn,t even know was an option." ... trial to evaluate the safety and effectiveness of the Microvention ...
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... NEW YORK (July 8, 2014) Researchers from ... College of Medicine of Yeshiva University will present ... being held July 12 July 17 in Copenhagen, ... triggers that could prompt transition from cognitive normality to ... of the Einstein Aging Study , established in ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... , BERKELEY HEIGHTS, N.J., Aug. 24 ... provider of secure Health Information Exchange and workflow management services, ... provider of home healthcare services and medical equipment, selected Authentidate,s ... with physicians. , , "We believe that ...
... , Expect the Unexpected - Boost Your ... Aug. 24 New York Blood Center (NYBC) and its regional ... and New Jersey urge healthy people to please donate blood now ... for predictable, as well as unexpected, blood needs. NYBC also ...
... , DOYLESTOWN, Pa., Aug. 24 Medical ... received European CE Mark (Conformite Europeene) approval to commercialize its ... for use in improving coronary artery luminal diameter in patients ... The novel vProtect(TM) Luminal Shield has the potential to change ...
... , , SIGNAL HILL, Calif., ... systems integrator transforming critical care, announced that it has received ... for additional enhancements of the company,s MedEx 1000(TM) "suitcase" intensive ... funds were included in an earlier announcement, we have confirmed ...
... Dr. Mark ... and is giving patients in Texas new reasons to smile. , ... (Vocus) August 24, 2009 -- Mark Sweeney, DDS knows cosmetic dentistry… and ... director of Austin Dental Spa , a practice devoted to turning visits to the dentist ...
... , ... largest primary eye care practice in Delaware, has recently donated eye glasses to the "Unite ... the African nation of Ghana. In the attached photos, residents of Ghana are shown ... ...
Cached Medicine News:Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 2Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 3Health News:LifeCare Solutions Simplifies Healthcare Order Process Management with Authentidate's Inscrybe Healthcare 4Health News:Give Blood Today for Community Preparedness 2Health News:Give Blood Today for Community Preparedness 3Health News:vProtect Luminal Shield (TM) from Prescient Medical Receives CE Mark 2Health News:Integrated Medical Systems Receives $1.1 Million From the U.S. Department of Defense for Critical Enhancements of the World's First 'Suitcase' Intensive Care Unit 2Health News:Integrated Medical Systems Receives $1.1 Million From the U.S. Department of Defense for Critical Enhancements of the World's First 'Suitcase' Intensive Care Unit 3Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 2Health News:Austin Texas Cosmetic Dentist Celebrates 30 Years in Practice 3Health News:Simon Eye Associates Donates to "Unite For Sight" Efforts in Ghana 2
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: